{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-140010","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.957062+00:00","generated_at":"2026-06-15T05:48:57.161075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alaunos Q1 net loss $10M; debt-free after SVB loan prepayment; expects interim TCR-T data Q3","bullets":["Net loss of $10.0M ($0.04/share) vs $9.8M ($0.05) in Q1 2022; R&D expenses up 17% to $6.5M.","Fully prepaid $11.0M SVB loan in May 2023; now debt-free; restricted cash of $13.9M released.","Interim clinical data from TCR-T Library Phase 1/2 trial expected Q3 2023; cryopreserved products manufactured.","Amended Precigen license: eliminated all royalties and milestones; retained exclusive rights to TCRs using Sleeping Beauty.","Cash $37.4M at March 31; expects cash into Q4 2023; 2023 operating outflows $35-40M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-140010","json":"https://secwatch.observer/filing/0001193125-23-140010.json","markdown":"https://secwatch.observer/filing/0001193125-23-140010.md","text":"https://secwatch.observer/filing/0001193125-23-140010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/0001193125-23-140010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/d459099d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:48:57.161075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2b9ad6952031188bda670ef088c9ca8a0b87dfa","claim":"Alaunos Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.0 million, EPS $(0.04) per share.","evidence_excerpt":"Net loss was $10.0 million, or $(0.04) per share, for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/0001193125-23-140010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$10.0 million"},{"label":"EPS","value":"$(0.04) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}